Figure 1. Dot plot comparisons of clinical and biochemical
parameters in women with FHA versus women with PCOS. Body mass index
kg/m2 (BMI, A), endometrial thickness (mm) (B),
luteinising hormone (LH, C), follicle-stimulating hormone; (FSH, D),
luteinising hormone: follicle-stimulating hormone ratio (FSH: LH ratio,
E),estradiol (F), thyroid-stimulating hormone (TSH, G), free thyroxine
(fT4, H) and prolactin (I) values in the functional hypothalamic
amenorrhoea (FHA) and polycystic ovary syndrome (PCOS) groups.
Comparisons between women with FHA and PCOS were made where
>50% of data was present and are summarised in Table 1. *
denotes where differences between FHA and PCOS groups were statistically
significant at p < 0.05. Error bars represent population mean
and standard deviation.
Figure 2. Diagnostic performance of clinical and biochemical
parameters for differentiating women FHA from women with PCOS. Receiver
operating characteristic curves for Body mass index
kg/m2 (BMI, A) and endometrial thickness (mm) (B),
luteinising hormone (LH, C), follicle-stimulating hormone; (FSH, D),
luteinising hormone: follicle-stimulating hormone ratio (FSH: LH ratio,
E),estradiol (F), thyroid-stimulating hormone (TSH, G), free thyroxine
(fT4, H) and prolactin (I) Abbreviation: AUC, area under the curve.
AUC=1 indicated perfect distinction between FHA and PCOS, whilst AUC=0.5
indicated no different from random selection. Red dotted line =
performance of random chance.